Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CKD-385 High-dose in Healthy Volunteers
NCT04906785Phase 1Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jun 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of carvedilol in cardiovascular diseases (CVD) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoint: Area Under the Curve from time zero to last quantifiable concentration. Status: unknown.
02
Drugs
carvedilol
03
Conditions
cardiovascular diseases (CVD)
Beyond the preview
Go deeper on NCT04906785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04906785.